A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer

Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 837127
Main Authors McNally, Christopher J, Watt, Joanne, Kurth, Mary Jo, Lamont, John V, Moore, Tara, Fitzgerald, Peter, Pandha, Hardev, McKenna, Declan J, Ruddock, Mark W
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.05.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies. Serum samples and clinical information were collected from = 125 age-matched patients ( = 61 non-PCa and = 64 PCa) and analyzed using Biochip Array Technology on high-sensitivity cytokine array I (IL-2, IL-4, IL-6, IL-8, IL-10, IL-1α, IL-1β, TNFα, MCP-1, INFγ, EGF, and VEGF), cerebral array II (CRP, D-dimer, neuron-specific enolase, and sTNFR1), and tumor PSA oncology array (fPSA, tPSA, and CEA). The data showed that 11/19 (68.8%) markers were significantly different between the non-PCa and the PCa patients. A combination of EGF, log IL-8, log MCP-1, and log tPSA significantly improved the predictive potential of tPSA alone to identify patients with PCa (DeLong, < 0.001). This marker combination had an increased area under the receiver operator characteristic (0.860 . 0.700), sensitivity (78.7 . 68.9%), specificity (76.5 . 67.2%), PPV (76.2 . 66.7%), and NPV (79.0 . 69.4%) compared with tPSA. The novel combination of serum markers identified in this study could be employed to help triage patients into "low-" and "high-risk" categories, allowing general practitioners to improve the management of patients in primary care settings and potentially reducing the number of referrals for unnecessary, invasive, and costly treatments.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors share senior authorship
Edited by: Antonina Mitrofanova, The State University of New Jersey, United States
Reviewed by: Gian Maria Busetto, University of Foggia, Italy; Andrea Benedetto Galosi, Marche Polytechnic University, Italy
This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.837127